Will the new developments be the equivalent of walking down the steps rather than the steep climb up of late?

Targeting cytokines – once seen as the next big thing in immuno-oncology (IO) – has been falling by the wayside as researchers and companies alike found them much trickier than expected to incorporate into cancer therapeutics.

Part of the problem lies in their pleiotropic nature – they can have an inhibitory or a stimulatory effect depending on the situation they encounter.

In our latest post on this niche we focus on one particular cytokine, which has long frustrated oncology companies,  regardless of the modality deployed.

With the new round of early data reveals, we take a look at whether several different next generation approaches are harnessing the complicated nuances at play, and in the process changing things for the better…

To learn more from our latest oncology expert interview and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by